Metrics as of 10/13/2026, 06:39 PM (Berlin time), refresh in progress.
Kyverna Therapeutics Stock
Kyverna Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Warner Biddle
- Employees
- 149
- Market cap
- $351 M
- IPO
- 09/02/2024
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis,…
Kyverna Therapeutics stock: price history
1D
-7.1%
1W
-6.3%
1M
-20.5%
6M
-38.4%
YTD
-38.6%
1Y
-16.7%
2Y
+9.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~6% weaker price swings than usual
Ask the agents about Kyverna Therapeutics
Analyst assessment of Kyverna Therapeutics
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 03/06/2026
Kyverna Therapeutics stock metrics
P/E
-1.96
P/B
2.12
EV/EBITDA
-2.36
RETURN ON EQUITY
-23.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.2
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
45.3%
FLOAT SHARES
27,530,267
AVG. DAILY VOLUME (30D)
942,878
Insider transactions (SEC)
Aktar Mert
Shaw Christi
SEIDENBERG BETH C
Cohen Fred E
CLARK IAN T
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Kyverna Therapeutics stock
What does Kyverna Therapeutics do?
Kyverna Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Warner Biddle, the company employs around 149 people.
The IPO was on 09/02/2024; the stock trades on NASDAQ under the ticker KYTX.
What do analysts say about Kyverna Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 03/06/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Kyverna Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Kyverna Therapeutics pay a dividend?
No, Kyverna Therapeutics currently does not pay a dividend.
Which stocks are comparable to Kyverna Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kyverna Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kyverna Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.